[Impact of HLA compatibility on the outcome of allogeneic hematopoietic stem cell transplantation for XXXX ].

@entity1 @entity6051 @entity9638 @entity786 @entity205 @entity2132 @entity1500 @entity1499 @entity1860 @entity1349
OBJECTIVE: To analyze the influence of HLA compatibility on the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in @entity1 with @entity1860 ( @entity1860 ). METHODS: This retrospective study involved 121 @entity1860 @entity1 including 90 in chronic phase, 8 in accelerated phase and 23 with @entity9638 . Of these @entity1 , 85 received related and 36 had unrelated donor allo-HSCT. The conditioning regimens included total body irradiation with @entity786 in 37 @entity1 , and modified BUCY protocol in 84 @entity1 . @entity205 (CsA) and @entity1499 ( @entity1500 ) were used for @entity2132 ( @entity2132 ) prophylaxis in @entity1 undergoing HLA-matched sibling donor transplants. CsA, @entity1500 , antihuman thymocyte globulin and @entity6051 were used in all the @entity1 undergoing HLA-mismatched related donor and unrelated donor transplants. The prognostic factors of @entity1860 were evaluated using Cox regression and the cumulative @entity1349 and the disease-free survival were estimated using Kaplan and Meier survival analysis model. RESULTS: The incidence of II-IV acute @entity2132 was 26.1% in HLA-matched and 53.3% in HLA-mismatched cases (P=0.006), with a 5-year cumulative incidence of chronic @entity2132 of 47.4% and 49.6%, respectively (P=0.947). The 5-year cumulative incidences of disease relapse was 16.7% in the total @entity1 , with a 5-year cumulative @entity1349 ( @entity1349 ) of 70.5% and disease-free survival (DFS) of 63.4%. The 5-year @entity1349 was 78.2% in HLA-matched cases, as compared with 47.6% in HLA-mismatched cases. Multivariate analysis with Cox regression model identified HLA mismatch, II-IV acute @entity2132 , and advanced phase as the risk factors affecting the @entity1349 . CONCLUSION: HLA mismatch can significantly increase the incidence of II-IV acute @entity2132 following allo-HSCT and decrease the long-term survival rate, which is not related to the donor source.
